The combined treatment was associated with a reduced risk of biochemical and clinical progression compared with radiotherapy alone.
Danish study reveals a 10% prevalence of osteoporosis among men due to start androgen-deprivation therapy.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
The treatment, however, is associated with a decreased risk of all-cause mortality in men at high risk of disease progression.
It is beneficial in terms of muscle strength, cardiorespiratory fitness, functional task performance, lean body mass, and fatigue.
Liberal use of androgen deprivation therapy likely gave prostate cancer patients a fracture risk comparable to that of the cancer itself.
Acute kidney injury was most likely to develop in men receiving combined androgen blockade.
Study reveals lower risk of developing castrate-resistant prostate cancer.
Integrated prostate cancer centers have greater use of intensity modulated radiation therapy.
Testosterone takes a long time to recover, so PSA levels in prostate cancer patients may remain low.
While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.
A large, international trial has found intermittent ADT is not equivalent to continuous ADT.
Data support prophylactic use of a PDE-5 inhibitor in men receiving radiotherapy for prostate cancer.
Nearly 189,000 men with nonmetastatic disease are receiving continuous ADT for six months or more, researchers estimate.
Men with prostate cancer receiving ADT who experience a fracture may have a 1.38-fold higher mortality risk.
Risk is unaffected by orchiectomy, large Danish study finds.
Elevated risk of gallbladder problems found with use of GnRH agonists.
Researchers concluded that exercise be considered as an adjunctive therapy in men undergoing androgen suppression.
Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.
The estimated seven-year cumulative rates of prostate cancer-related death were 18% and 15%, respectively, for intermittent and continuous androgen suppression.
New data indicate a sustained and substantial overall and disease-specific survival benefit associated with androgen deprivation therapy (ADT) plus radiation therapy among patients with locally advanced prostate cancer.
Recent studies have looked at the use of intermittent ADT as way to spare prostate cancer (PCa) patients some of the adverse effects associated with continuous ADT.
Androgen deprivation therapy (ADT) prior to salvage cryotherapy does not improve biochemical-free survival (BFS) at five years, according to data presented at the American Urological Association 2012 annual meeting.
Adding radiotherapy to androgen deprivation therapy (ADT) improves outcomes in patients with locally advanced prostate cancer (PCa) and can be considered a standard treatment option.
Study finds loss evident in men treated with ADT for nonmetastatic, hormone-sensitive prostate cancer
Use of short-course androgen deprivation therapy (ADT) may improve overall and disease-specific survival but does not appear to increase cardiovascular mortality in men with clinically-localized prostate cancer.
Combined external beam radiation therapy (EBRT) with a brachytherapy boost plus androgen deprivation therapy (ADT) is associated with excellent disease-free survival among men with intermediate-risk prostate cancer (PCa), researchers reported.
Initiation of androgen deprivation therapy (ADT) for prostate cancer (PCa) is declining and patterns of use are changing, according to recently published data from a Canadian study.
Obesity is associated with an increased risk for prostate cancer (PCa) progression among PCa patients treated with androgen deprivation therapy (ADT) after radical prostatectomy, according to a study.
The FDA has approved denosumab (Prolia) as a treatment to increase bone mass in prostate cancer patients at high risk for fracture undergoing androgen deprivation therapy (ADT) and women with breast cancer at high risk for fracture who are receiving aromatase inhibitor therapy.